Glycoengineering of Therapeutic Glycoproteins: In Vitro Galactosylation and Sialylation of Glycoproteins with Terminal N-Acetylglucosamine and Galactose Residues
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Therapeutic glycoproteins produced in different host cells by recombinant DNA technology often contain terminal GlcNAc and Gal residues. Such glycoproteins clear rapidly from the serum as a consequence of binding to the mannose receptor and/or the asialoglycoprotein receptor in the liver. To increase the serum half-life of these glycoproteins, we carried out in vitro glycosylation experiments using TNFR-IgG, an immunoadhesin molecule, as a model therapeutic glycoprotein. TNFR-IgG is a disulfide-linked dimer of a polypeptide composed of the extracellular portion of the human type 1 (p55) tumor necrosis factor receptor (TNFR) fused to the hinge and Fc regions of the human IgG(1) heavy chain. This bivalent antibody-like molecule contains four N-glycosylation sites per polypeptide, three in the receptor portion and one in the Fc. The heterogeneous N-linked oligosaccharides of TNFR-IgG contain sialic acid (Sia), Gal, and GlcNAc as terminal sugar residues. To increase the level of terminal sialylation, we regalactosylated and/or resialylated TNFR-IgG using beta-1,4-galactosyltransferase (beta1,4GT) and/or alpha-2,3-sialyltransferase (alpha2,3ST). Treatment of TNFR-IgG with beta1,4GT and UDP-Gal, in the presence of MnCl(2), followed by MALDI-TOF-MS analysis of PNGase F-released N-glycans showed that the number of oligosaccharides with terminal GlcNAc residues was significantly decreased with a concomitant increase in the number of terminal Gal residues. Similar treatment of TNFR-IgG with alpha2,3ST and CMP-sialic acid (CMP-Sia), in the presence of MnCl(2), produced a molecule with an approximately 11% increase in the level of terminal sialylation but still contained oligosaccharides with terminal GlcNAc residues. When TNFR-IgG was treated with a combination of beta1,4GT and alpha2,3ST (either in a single step or in a stepwise fashion), the level of terminal sialylation was increased by approximately 20-23%. These results suggest that in vitro galactosylation and sialylation of therapeutic glycoproteins with terminal GlcNAc and Gal residues can be achieved in a single step, and the results are similar to those for the stepwise reaction. This type of in vitro glycosylation is applicable to other glycoproteins containing terminal GlcNAc and Gal residues and could prove to be useful in increasing the serum half-life of therapeutic glycoproteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parekh, R. B., Dwek, R. A., Sutton, B. J., Fernandes, D. L., Leung, A., Stanworth, D., Rademacher, T. W., Mizuochi, T., Taniguchi, T., Matsuta, K., et al. (1985) · Nature · doi:10.1038/316452a0 · Cited by 1,170
Cited by
Sialic acids in human health and disease
Varki, A. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.06.002 · Cited by 999
Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc
Anthony, R. M., Nimmerjahn, F., Ashline, D. J., Reinhold, V. N., Paulson, J. C., & Ravetch, J. V. (2008) · Science · doi:10.1126/science.1154315 · Cited by 849
Optimal and consistent protein glycosylation in mammalian cell culture
Hossler, P., Khattak, S. F., & Li, Z. J. (2009) · Glycobiology · doi:10.1093/glycob/cwp079 · Cited by 669
Terminal sugars of Fc glycans influence antibody effector functions of IgGs
Raju, T. S. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.007 · Cited by 521
Self-citationBody, J.-J., Facon, T., Coleman, R. E., Lipton, A., Geurs, F., Fan, M., Holloway, D., Peterson, M. C., & Bekker, P. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1933 · Cited by 490
Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals
Butler, M. (2005) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-005-1980-8 · Cited by 469
Glycosylation of Therapeutic Proteins: An Effective Strategy to Optimize Efficacy
Solá, R. J., & Griebenow, K. (2010) · BioDrugs · doi:10.2165/11530550-000000000-00000 · Cited by 440
Protein glycosylation in bacterial mucosal pathogens
Szymanski, C. M., & Wren, B. W. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1100 · Cited by 402
Scallon, B. J., Tam, S. H., McCarthy, S. G., Cai, A. N., & Raju, T. S. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2006.09.005 · Cited by 396
Self-citationEnzyme technology: an overview
Beilen, J. B. V., & Li, Z. (2002) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(02)00334-8 · Cited by 320
Ferrara, C., Brünker, P., Suter, T., Moser, S., Püntener, U., & Umaña, P. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20777 · Cited by 305
“For this purpose, EndoH analysis was combined with in vitro galactosylation of the whole antibody performed as described (Raju et al., 2001).”
MethodAlt, N., Zhang, T. Y., Motchnik, P., Taticek, R., Quarmby, V., Schlothauer, T., Beck, H., Emrich, T., & Harris, R. J. (2016) · Biologicals · doi:10.1016/j.biologicals.2016.06.005 · Cited by 294
In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity
Thomann, M., Schlothauer, T., Dashivets, T., Malik, S., Avenal, C., Bulau, P., Rüger, P., & Reusch, D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0134949 · Cited by 220
“140 not broadly applied in the pharmaceutical industry even though this technique has been used for more than a decade for different, mostly analytical, purposes.(21-25) One advantage of in vitro glycoengineering is its independence from the production cell line and the production process.”
MethodProduction of α2,6-sialylated IgG1 in CHO cells
Raymond, C., Robotham, A., Spearman, M., Butler, M., Kelly, J., & Durocher, Y. (2015) · mAbs · doi:10.1080/19420862.2015.1029215 · Cited by 106
Production of Highly Sialylated Monoclonal Antibodies
Raymond, C., Robotham, A., Kelly, J., Lattova, E., Perreault, H., & Durocher, Y. (2012) · Glycosylation · doi:10.5772/51301 · Cited by 20
“Several approaches are used to enhance the sialylation level of recombinant proteins produced in mammalian cell cultures, such as cell line engineering, bioprocess control, postproduction enrichment (such as lectin-affinity purification) and in vitro glycan remodelling [27, 40].”
MethodKim, S.-M., Chang, K.-H., & Oh, D. J. (2018) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-018-0109-8 · Cited by 11
Soft sensing of intracellular states for CHO cell bioprocessing with Ensemble Kalman Filters
Yu, L., del Rio Chanona, A., & Kontoravdi, C. (2026) · Journal of Process Control · doi:10.1016/j.jprocont.2026.103875
Metadata
- Authors
- Raju, T. S., Briggs, J. B., Chamow, S. M., Winkler, M. E., & Jones, A. J. S.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2001-07-01
- Volume
- 40
- Issue
- 30
- Pages
- 8868-8876
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2016901072
- Cited by
- 122
- References
- 1
- FWCI
- 0.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.